References
- Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154–1163.
- Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc 2006;81:247–260.
- Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Progress in the treatment of acute myeloid leukemia. Cancer 2007;110:1900–1910.
- Daenen S, Lowenberg B, Sonneveld P, et al Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology–Oncology Working Group for Adults (HOVON). Leukemia 1994;8:6–10.
- Ehninger G, Fackler-Schwalbe E, Freund M, et al Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. Haematol Blood Transfus 1990;33:316–317.
- Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia – an active and well-tolerated regimen. J Clin Oncol 1988;6:213–217.
- Knauf WU, Berdel WE, Ho AD, Kreuser ED, Thiel E. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymphoma 1994;12:421–425.
- Lazzarino M, Morra E, Alessandrino EP, et al Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia. Eur J Haematol 1989;43:411–416.
- O'Brien S, Kantarjian H, Estey E, et al Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 1991;68:691–694.
- Paciucci PA, Davis RB, Holland JF, Martelo O, Schiffer CA. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol 1990;13:516–519.
- Slovak ML, Kopecky KJ, Cassileth PA, et al Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–4083.
- Cheson BD, Bennett JM, Kopecky KJ, et al Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642–4649.
- Biggs JC, Horowitz MM, Gale RP, et al Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992;80:1090–1093.
- Fung HC, Stein A, Slovak M, et al A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003;9:766–771.
- Song KW, Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. Bone Marrow Transplant 2005;36:183–191.
- A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998;103:100–109.
- Bennett JM, Lymann GH, Cassileth PA, Glick JH, Oken MM. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1984;7:471–473.
- Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 1983;67:389–390.
- Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF. Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 1983;43:3919–3922.
- Smith IE, Gerken ME, Clink HM, McElwain TJ. VP 16-213 in acute myelogenous leukaemia. Postgrad Med J 1976;52:66–70.
- Jourdan E, Reiffers J, Stoppa AM, et al Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group. Leuk Lymphoma 2001;42:57–65.
- Anderlini P, Ghaddar HM, Smith TL, et al Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 1996;10:964–969.